MILIND JAVLE to Antineoplastic Agents, Immunological
This is a "connection" page, showing publications MILIND JAVLE has written about Antineoplastic Agents, Immunological.
Connection Strength
0.490
-
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021 09; 22(9):1290-1300.
Score: 0.410
-
Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. Oncologist. 2018 03; 23(3):277-e26.
Score: 0.080